BioCentury | Dec 20, 2019
Emerging Company Profile

Centaurus: inhibiting ceramide synthesis for cardiometabolic disease

...a Sanofi (Euronext:SAN; NYSE:SNY) team reported in a Molecular Metabolism article that antisense oligonucleotides targeting CERS6...
...Investors: Undisclosed CEO: Jeremy Blitzer and Stephen Halasz Patents: None issued Targets CERS6 (LASS6) - Ceramide synthase 6...
BioCentury | Apr 26, 2019
Company News

Soriot sees progress in U.S.-China IP debate

AstraZeneca CEO Pascal Soriot said China is making progress on protecting biopharma IP, as the pharma reported 1Q19 earnings that saw a 28% increase year-over-year in sales in the country. "Everything we've seen happening over...
BioCentury | Apr 19, 2019
Company News

Newer drugs lift Roche’s 1Q sales

Driven by newer drugs and expanded indications, Roche beat analyst expectations for its 1Q19 global pharmaceutical sales by 7% at CHF11.9 billion ($11.8 billion) vs. the Street's CHF11.2 billion ($11 billion) estimate. Pharmaceutical sales increased...
BioCentury | Aug 3, 2018
Clinical News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
BioCentury | Jul 31, 2018
Company News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
BioCentury | May 24, 2018
Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
BioCentury | Apr 27, 2018
Company News

Sanofi's Dupixent misses sales estimates, Regeneron slips

Sanofi (Euronext:SAN; NYSE:SNY) reported 1Q18 earnings, including sales of atopic dermatitis drug Dupixent dupilumab that missed estimates. The company's partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slid $10.92 to $313.05 on the news Friday, shedding nearly $1.2...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BioCentury | Aug 11, 2016
Company News

Management tracks

Cancer company Oric Pharmaceuticals Inc. (South San Francisco, Calif.) named Ashraf Hanna CEO and Darcy Mootz CBO. Hanna was VP of commercial and medical affairs finance at the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY). Mootz...
Items per page:
1 - 10 of 358